Gastrointestinal Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_13_2136 - Comparison of Stereotactic Body Radiation Therapy Combined with or without Transcatheter Arterial Chemoembolization for Patients with Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Comparison of Stereotactic Body Radiation Therapy Combined with or without Transcatheter Arterial Chemoembolization for Patients with Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies
T. Kimura1, Y. Doi2, H. Aikata3, N. Imano1, Y. Takeuchi1, I. Takahashi1, I. Nishibuchi1, T. Katsuta2, M. Kenjo2, Y. Murakami1, K. Awai4, K. Chayama3, and Y. Nagata5; 1Department of Radiation Oncology, Hiroshima University, Hiroshima, Japan, 2Department of Radiation Oncology, Hiroshima High-precision Radiotherapy Cancer Center, Hiroshima, Japan, 3Department of Medicine and Molecular Science, Hiroshima University, Hiroshima, Japan, 4Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, 5Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan

Purpose/Objective(s): To compare the efficacy and safety of stereotactic body radiation therapy (SBRT) with or without transcatheter arterial chemoembolization (TACE) for patients with small hepatocellular carcinoma (HCC) who were ineligible for resection or ablation therapies.

Materials/Methods: A total of 150 patients with 185 HCCs (≤3 nodules, Child- Turcotte -Pugh class A or B, and no vascular or extrahepatic metastases) were treated with SBRT. Inprinciple, TACE was combined before SBRT (combination group), but some patients were treated with SBRT alone (SBRT alone group). The prescribed dose of SBRT was 48Gy in four fractions at the isocenter, 40 Gy in four or five fractions at the D95% of the planning target volume. The overall survival (OS), progression-free survival (PFS), local progression free survival (LPFS) and complication rates were retrospectively compared between the groups. Local progression was defined as irradiated tumor growth in dynamic computed tomography follow- up. Tumor responses were assessed according to the modified Response Evaluation Criteria in Solid Tumors. Treatment- related toxicities were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0.

Results: Twenty-eight patients and 122 patients were enrolled in the SBRT alone and combination groups, respectively. The median follow-up periods werw 16 and 29 months, respectively. The two- year OS, PFS and LPFS in SBRT alone or combination group were 78.6 % and 80.3 % (p = 0.6583), 49.0 % and 42.9 % (p =0.188), 71.4 % and 80.8 % (p = 0.9661), respectively. The incidence of ≥ Grade 3 toxicities was 17.9 % in SBRT alone group and 18.9 % in combination group (p =0.903).

Conclusion: There were no significant difference of survivals and adverse effects for patients with small HCCs who were performed SBRT with or without TACE. SBRT alone may be a good treatment option for patients with small HCC who were ineligible for resection or ablation therapies.

Author Disclosure: T. Kimura: None. Y. Doi: None. N. Imano: None. Y. Takeuchi: None. I. Takahashi: None. I. Nishibuchi: None. T. Katsuta: None. K. Awai: None.

Send Email for Tomoki Kimura


Assets

SU_13_2136 - Comparison of Stereotactic Body Radiation Therapy Combined with or without Transcatheter Arterial Chemoembolization for Patients with Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Comparison of Stereotactic Body Radiation Therapy Combined with or without Transcatheter Arterial Chemoembolization for Patients with Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies